U-Blot® Research Grade Zansecimab

Name: U-Blot® Research Grade Zansecimab
SKU: WA3826
Availability: InStock

$9,999.00

Size:50ug

SKU: WA3826-50

Catalog No.: WA3826

Specification: 50ug/100ug

Stock: In stock

U-Blot® Research Grade Zansecimab Learn more

Product details Specifications Q & A Education

U-Blot® Research Grade Zansecimab

Product Overview

Catalog No.: WA3826
SKU: WA3826-50
Category: Biosimilar Antibodies
Product Type: Other
Size: 50ug/100ug
Stock Status: In stock
Available Stock: 999
Minimum Order Quantity: 1

Storage & Compliance

Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Research Use Only: Yes

Additional Specifications

PackSize: 50ug/100ug
Target: ANG-2
Reactivity: Human
Applications: ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host Species: Humanized
Isotype: IgG4-Kappa
Conjugate/Modification: --
Recommended Dilution Ratio: --
Composition: 0.01M PBS, pH 7.4.
Purification Process: Protein A/G purified from cell culture supernatant.
Purity: >95% purity as determined by SDS-PAGE.
storageCondition: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Clonality: Monoclonal
Clone Number: --
Immunogen: Mammalian Cells
Alias: ANG-2, ANGPT2, Angiopoietin-2
Species: --
Gene ID-1: O15123
Uniprot: --
Background: Trebananib (2xCon4C; AMG 386) is an Fc fusion peptibody that prevents Tie2 receptor activation through binding of both angiopoietin 1 (Ang1) and Ang2. Trebananib has anti-angiogenesis activity. • Role of Angiopoietin-2 in Vascular Physiology and Pathophysiology., PMID:31108880 • Acute respiratory distress syndrome., PMID:30872586 • Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials., PMID:38158159 • Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials., PMID:35085502 • Efficacy and Safety of Faricimab for Macular Edema due to Retinal Vein Occlusion: 24-Week Results from the BALATON and COMINO Trials., PMID:38280653 • TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2., PMID:38382813 • Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial., PMID:30905643 • Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials., PMID:35085503 • Blocking the angiopoietin-2-dependent integrin β-1 signaling axis abrogates small cell lung cancer invasion and metastasis., PMID:38775153 • Loss of TGFβ-Mediated Repression of Angiopoietin-2 in Pericytes Underlies Germinal Matrix Hemorrhage Pathogenesis., PMID:39129597
Tissue Expression: --
Signaling_pathway: --
Research Areas: --

Tech Support

ucallm

Documents

Datasheet, COA, SDS, and protocol files can be requested from technical support.

Storage & Handling

Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.